hrcak mascot   Srce   HID

Review article

Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness

Petra Marić
Petar Ozretić
Sonja Levanat
Slavko Orešković
Katarina Antunac
Lidija Beketić-Orešković

Fulltext: english, pdf (88 KB) pages 241-247 downloads: 1.038* cite
APA 6th Edition
Marić, P., Ozretić, P., Levanat, S., Orešković, S., Antunac, K. & Beketić-Orešković, L. (2011). Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness. Collegium antropologicum, 35 (1), 241-247. Retrieved from https://hrcak.srce.hr/64795
MLA 8th Edition
Marić, Petra, et al. "Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness." Collegium antropologicum, vol. 35, no. 1, 2011, pp. 241-247. https://hrcak.srce.hr/64795. Accessed 19 Oct. 2020.
Chicago 17th Edition
Marić, Petra, Petar Ozretić, Sonja Levanat, Slavko Orešković, Katarina Antunac and Lidija Beketić-Orešković. "Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness." Collegium antropologicum 35, no. 1 (2011): 241-247. https://hrcak.srce.hr/64795
Harvard
Marić, P., et al. (2011). 'Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness', Collegium antropologicum, 35(1), pp. 241-247. Available at: https://hrcak.srce.hr/64795 (Accessed 19 October 2020)
Vancouver
Marić P, Ozretić P, Levanat S, Orešković S, Antunac K, Beketić-Orešković L. Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness. Collegium antropologicum [Internet]. 2011 [cited 2020 October 19];35(1):241-247. Available from: https://hrcak.srce.hr/64795
IEEE
P. Marić, P. Ozretić, S. Levanat, S. Orešković, K. Antunac and L. Beketić-Orešković, "Tumor Markers in Breast Cancer – Evaluation of their Clinical Usefulness", Collegium antropologicum, vol.35, no. 1, pp. 241-247, 2011. [Online]. Available: https://hrcak.srce.hr/64795. [Accessed: 19 October 2020]

Abstracts
Breast cancer is the most common neoplasm affecting women in the Western world. Many studies are still conducted
with the purpose of finding markers that could be used for early diagnosis and/or serve as possible reliable prognostic or
predictive parameters, but with conflicting results. At present, no markers are available for an early diagnosis of breast
cancer. For surveillance of patients with diagnosed breast cancer the most widely used serum markers are CA 15-3 and
CEA which, in combination with other clinical parameters, could have clinical significance. The most useful and clinically
important tissue-based markers in breast cancer are estrogen and progesterone receptors, used as a basis for hormonal
therapy, and HER-2 receptors, essential in selecting patients for the treatment with Herceptin®. New or potentially
new markers for breast cancer include BRCA1 and BRCA2 genes for selecting patients at high risk of developing
hereditary breast cancer, as well as urokinase plasminogen activator and inhibitor for assessing prognosis in lymph
node-negative patients. Results of tumor and patient genetic analyses including their clinical evaluation will enable application
of more individualized and personalized approach in diagnosis and therapy of breast cancer patients.

Keywords
breast cancer; serum tumor markers; tissue tumor markers; genetic tumor markers; clinical application

Hrčak ID: 64795

URI
https://hrcak.srce.hr/64795

Visits: 1.320 *